Phaseline

Companies › Fujifilm Pharmaceuticals U.S.A.

Fujifilm Pharmaceuticals U.S.A.: clinical trials, targets and expected readouts

1 active drug program in 9 registered trials: 4 Phase 1, 3 Phase 2, 2 Phase 3; Oncology, Ophthalmology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Topotecan (FF-10850)
DNA topoisomerase I inhibitor
TOP1Phase 1Advanced Solid Tumors; Retinoblastoma; Pleuropulmonary Blastoma; Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment …Dec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05523869Topotecan (FF-10850)Phase 2Proliferative Vitreoretinopathy in Rhegmatogenous Retinal DetachmentOphthalmologyFeb 2026
NCT04047251Topotecan (FF-10850)Phase 1Advanced Solid TumorsOncologyDec 2026
NCT01783535Topotecan (FF-10850)Phase 2RetinoblastomaOncologyFeb 2027
NCT04799002Topotecan (FF-10850)Phase 3RetinoblastomaOncologyDec 2027
NCT06666712Topotecan (FF-10850)Phase 1Brain Tumor, RecurrentOncologyJan 2028
NCT06647953Topotecan (FF-10850)Phase 3Pleuropulmonary BlastomaOncologyMar 2029
NCT07334301Topotecan (FF-10850)Phase 1Relapsed NeuroblastomaOncologyDec 2030
NCT02813135Topotecan (FF-10850)Phase 1Pediatric CancerOncologyFeb 2031
NCT04681417Topotecan (FF-10850)Phase 2RetinoblastomaOncologyJan 2035

Targets

TOP1 (1)

Companies with the same targets

Daiichi Sankyo AstraZeneca Merck & Co. (MSD) Gilead Sciences Klus Pharma Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB Chair Targeted Therapy Technologies CEBIOTEX Sichuan Kelun-Biotech Biopharmaceutical Luye Pharma Group

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.